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L E T T E R TO TH E E D I T O R
Soluble FcɛRI: A biomarker for IgE‐mediated diseases
To the Editor,
Soluble IgE receptors interact with IgE in the extracellular matrix and
are important in the regulation of immune diseases.1-5 Soluble FcεRII
(sCD23) and galectin‐3 (εBP) are currently used as biomarkers,1
though correlation data on serum titers and severity of allergies are
controversial.1,6
FcεRI, the high‐affinity IgE Fc receptor, is expressed on several
innate cell types,2 and a truncated version of the IgE‐binding alpha
subunit is found as a soluble isoform (sFcεRI) in human serum. In cir-
culation, sFcεRI is mostly detected as a complex with IgE.7 This
observation raises the question of how sFcεRI affects detection of
serum IgE titers.
In order to assign clinical implications of sFcεRI, we assessed
serum titers in its total and IgE‐bound forms in different IgE‐
mediated diseases in 312 individuals. We compared pediatric popula-
tions with primary food allergies (n = 59), insect venom allergies
(n = 9), allergic asthma (n = 24), atopic dermatitis (n = 25), food‐sen-
sitized nonallergic children (n = 31), and nonallergic controls (n = 17).
Additionally, other sensitized groups and controls (n = 147) were
included in the study (Table S1-S4).
SFCΕRI IS ELEVATED IN SERUM OF ATOPIC
INDIVIDUALS AND IS MODULATED BY ALLERGEN
EXPOSURE
Serum samples were analyzed by ELISA to detect IgE‐bound and total
serum sFcεRI levels (Figure S1). First, sFcεRI was ubiquitously detect-
able among controls (median 1.20 ng/mL) but titers were significantly
higher in atopic individuals (median 2.88 ng/mL, Figure 1A and Table
S1). In line with previous studies,7,8 IgE and sFcεRI levels correlated
positively in all patients, and sFcεRI in circulation was almost uniquely
detected as a complex with IgE (Figure 1B,C). Next, we grouped the
atopic individuals based on their main IgE‐mediated disease (Table S2)
as food allergy (FA), insect venom allergy (IV), allergic asthma (AA), or
atopic dermatitis (AD). AD, AA, and FA groups presented with signifi-
cantly higher sFcεRI levels than controls (Figure 1D).
Since IgE‐sensitization profiles toward food allergens are gener-
ally a poor measure of clinical symptoms, we compared sFcεRI titers
in two food‐sensitized nonallergic groups (FS and Ghana) with FA
patients (Table S3). The Ghana cohort showed similar correlations as
already described between IgE and sFcεRI, IgE‐bound and total
sFcεRI levels, and no correlation with peanut‐specific IgE (sIgE) titers.
No significant difference was detected with regards to disease activ-
ity among food‐sensitized individuals (Figure S2).
We then investigated whether serum sFcεRI levels were different
in patients diagnosed with atopic dermatitis or asthma, with (Pos
sIgE) or without (Neg sIgE) a clinically relevant sIgE profile. sFcεRI
titers did not differ based on the patients’ sIgE profile. However, we
found significantly higher titers in patients with elevated IgE (Fig-
ure S3) in both AD and AA groups (Figure 1E‐H).
Recently, we demonstrated that sFcεRI is released from dendritic
cells and mast cells after antigen‐specific FcεRI crosslinking.5 Thus,
we studied how sFcεRI levels in circulation are affected by allergen
exposure. We compared sFcεRI levels in AA individuals (n = 14 pairs)
during (In) and before/after (Out) season for their most clinically rele-
vant allergen (Table S4) and observed that serum levels could signifi-
cantly increase (50%) or decrease (50%) during season. This pattern
was similarly observed with total IgE levels (Figure S4). In order to
better determine the role of allergen exposure, we analyzed food‐
sensitized individuals on allergen avoidance (n = 13) during an oral
food challenge (Figure S5). We observed a general trend of sFcεRI
titers to decrease after allergen exposure (Figure 1I).
IGE:SFCΕRI COMPLEXES INTERFERE WITH IGE
DETECTION
sFcεRI binds to the Fc portion of IgE and can potentially interfere
with antibody binding to that region. We thus investigated whether
sFcεRI affects antibody‐based IgE detection. For this purpose, a
recombinant IgE‐binding protein (rsFcεRI) and a mutated version
which cannot bind IgE (rsFcεRIm) were generated. Prior to a commer-
cial IgE ELISA, samples containing human cIgE were incubated with
the recombinant proteins (Figure 2A‐C). Our hypothesis was that IgE
detection will be impaired and reflected in a decrease of IgE levels
with increasing concentrations of rsFcεRI. In Figure 2D, we show an
r = −0.867 with P = 0.005 which depicts a significant negative corre-
lation in support of our hypothesis. On the contrary, as shown in
Figure 2E, increasing concentrations of the mutant version of rsFcεRI
which is unable to bind IgE do not show interference in IgE detec-
tion (r = 0.349, ns). This interference with IgE detection by rsFcεRI
was confirmed with human IgE (Figure 2F) and human serum (n = 2)
Abbreviations: cIgE, chimeric humanized anti-NIP immunoglobulin E; DC, dendritic cell;
FcεRI, Fc epsilon Receptor I, high-affinity IgE Fc receptor; IgE, Immunoglobulin E; IQR,
interquartile range; MC, mast cell; OFC, oral food challenge; rsFcεRIm, mutant recombinant
human sFcεRI; rsFcεRI, recombinant human sFcεRI; sCD23, soluble isoform of CD23,
low-affinity IgE Fc receptor; sFcεRI, soluble isoform of FcεRI; sIgE, allergen-specific
immunoglobulin E; SPT, skin prick test; εBP, epsilon binding protein.
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from patients with elevated IgE levels (Figure 2G). In addition, we
observed that sFcεRI titers were significantly higher in serum than
plasma (Figure S6).
To the best of our knowledge, this is the first analysis of sFcεRI
levels in a pediatric population of well‐classified sensitized and aller-
gic individuals. We show that sFcεRI is correlated with IgE levels, is
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F IGURE 1 sFcεRI is highly expressed in allergic individuals and it is modulated by allergen exposure. Detection of total and IgE‐bound
sFcεRI levels by ELISA. Total sFcεRI levels in control and atopic (n = 148) groups (A). Correlation between total sFcεRI and total IgE levels in
atopic group (B). Total and IgE‐bound sFcεRI levels in atopic group (C). Total sFcεRI levels in control and IgE diseases groups (D). Total sFcεRI
levels with and without sIgE sensitizations, and normal and elevated IgE levels in AD (E‐F) and AA (G‐H). Total sFcεRI levels during OFC (I).
Graphs represent individuals with median plus IQR. Mann‐Whitney test (A, E‐H), Kruskal‐Wallis test plus Dunn's multiple correction (C), and
Spearman r coefficient ranks (B, D) were performed, where *P < 0.05, **P < 0.01, and ****P < 0.0001. Co: control (n = 17); IV: insect venom
(n = 9); AD: atopic dermatitis (n = 45); AA: allergic asthma (n = 69); FA: food allergy (n = 59); Pos: positive; Neg: negative; IQR: interquartile
range; OFC: oral food challenge (n = 13) [Color figure can be viewed at wileyonlinelibrary.com]
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significantly increased in IgE‐sensitized individuals, and can be modu-
lated by allergen exposure. We collected evidence that sFcεRI can
interfere with IgE detection in serum, which might be of importance
in regard to interference in sIgE detection and diagnosis. Although
further research on the modulation by allergen exposure and inter-
ference with sIgE molecules is needed, sFcεRI represents an addi-
tional biomarker for IgE‐mediated diseases and its use could be a
valuable tool in clinical practice.
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mL cIgE solution (D‐E). Detection of IgE
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